Drugs facing NCE-1 in 2030

1. List of Brexafemme drug patents

BREXAFEMME's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188085 SCYNEXIS Antifungal agents
Aug, 2030

(7 years from now)

US10174074 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

US10927142 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

US11534433 SCYNEXIS Antifungal agents with enhanced activity in acidic pH
Jun, 2039

(16 years from now)

Do you want to check out BREXAFEMME patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2026
New Indication (I) Nov 30, 2025
Generating Antibiotic Incentives Now (GAIN) Jun 1, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: 2030-06-01

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc); Reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatr...

Dosage: TABLET;ORAL

More Information on Dosage

BREXAFEMME family patents

8

United States

3

China

3

European Union

2

Hong Kong

1

Croatia

1

Poland

1

RS

1

Spain

1

Canada

1

Portugal

1

Lithuania

EA

1

EA

1

Denmark

1

Japan

1

Australia

1

Slovenia

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in